HER2 ADC population PK
A two-compartment population PK model for HER2-directed antibody–drug conjugates, representing central and peripheral disposition, concentration, and cumulative exposure across dose levels.
- Therapeutic
- Trastuzumab emtansine or trastuzumab deruxtecan, trastuzumab emtansine, T-DM1, trastuzumab deruxtecan, T-DXd, trastuzumab
- Target
- HER2 / ERBB2
- Disease
- HER2-positive cancers
Biological model
A two-compartment population PK model for HER2-directed antibody–drug conjugates, representing central and peripheral disposition, concentration, and cumulative exposure across dose levels.
Intervention
Trastuzumab emtansine or trastuzumab deruxtecan, trastuzumab emtansine, T-DM1, trastuzumab deruxtecan, T-DXd, trastuzumab
Biological focus
HER2 / ERBB2
Context
HER2-positive cancers
Model details
A two-compartment population PK model for HER2-directed antibody–drug conjugates, representing central and peripheral disposition, concentration, and cumulative exposure across dose levels.
Modeled states
- auc ng day mlng*day/mL
Modeled dynamic state for auc ng day ml.
- central mgmg
Modeled dynamic state for central mg.
- elapsed dayday
Modeled dynamic state for elapsed day.
- peripheral mgmg
Modeled dynamic state for peripheral mg.
Key readouts
- Central HER2 ADC concentrationunknown
Model-derived readout for central her2 adc concentration.
- Peripheral HER2 ADC concentrationunknown
Model-derived readout for peripheral her2 adc concentration.
- Cumulative ADC exposureng*day/mL
Model-derived readout for cumulative adc exposure.
- central conc mg lunknown
Model-derived readout for central conc mg l.
- central mgmg
Model-derived readout for central mg.
Explore this model
Choose a starting point to view its result. Adjust key model inputs when you want to explore a different outcome.
T-DM1 0.3 mg/kg cycle-1 fixed-effect
How does dose change HER2 ADC concentration and cumulative exposure? Explore this intervention regimen through Central HER2 ADC concentration, Peripheral HER2 ADC concentration, Cumulative ADC exposure. This is a mechanistic product exploration, not a paper-result reproduction.
Questions to explore
- How does dose change HER2 ADC concentration and cumulative exposure?
Starting result
This result reflects the starting settings. Run your changes to update it.
Model inputs
Five scientist-facing controls at most.
Compare a parameter
How does one model input change the response?
How does dose change HER2 ADC concentration and cumulative exposure?
cl l day
Model parameter controlling cl l day.
Exploratory range around the default value.
5 evenly spaced values in L/day. Other model inputs and the simulation window stay fixed.
Interpret with care
- Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.
- Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario.
Review the server-confirmed fixed price before starting the comparison.
Comparative response
End-of-window response across the selected parameter values.
Choose an exploratory range around the default, review the fixed price, and run the comparison.
Scientific reference
Supporting publication
Postmarketing Assessment of Antibody–Drug Conjugates: Proof‐of‐Concept Using Model‐Based Meta‐Analysis and a Clinical Utility Index ApproachCPT: Pharmacometrics & Systems Pharmacology
